1. Home
  2. RQI vs STOK Comparison

RQI vs STOK Comparison

Compare RQI & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Quality Income Realty Fund Inc

RQI

Cohen & Steers Quality Income Realty Fund Inc

HOLD

Current Price

$12.24

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

Logo Stoke Therapeutics Inc.

STOK

Stoke Therapeutics Inc.

HOLD

Current Price

$29.13

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RQI
STOK
Founded
2002
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.9B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
RQI
STOK
Price
$12.24
$29.13
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$34.50
AVG Volume (30 Days)
432.6K
712.6K
Earning Date
01-01-0001
03-17-2026
Dividend Yield
8.20%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.68
Revenue
N/A
$205,632,000.00
Revenue This Year
N/A
$430.24
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$43.03
Revenue Growth
N/A
1128.17
52 Week Low
$9.17
$5.35
52 Week High
$12.64
$38.69

Technical Indicators

Market Signals
Indicator
RQI
STOK
Relative Strength Index (RSI) 63.47 43.22
Support Level $12.01 $28.75
Resistance Level $12.25 $30.96
Average True Range (ATR) 0.17 2.05
MACD 0.04 -0.34
Stochastic Oscillator 93.04 33.14

Price Performance

Historical Comparison
RQI
STOK

About RQI Cohen & Steers Quality Income Realty Fund Inc

COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the fund is high current income through investment in real estate securities. Its secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Share on Social Networks: